Skip to main navigation
Vaxcyte
  • Mission
  • Pipeline
  • Approach
  • About Us
  • Investors & Media
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financials & Filings
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Email Alerts
      • IR Contact
      • Tax Disclosures
  • Careers
Select Page
  • RSS Feeds
  • Email Alerts
  • IR Contact

Event Details

Vaxcyte VAX-24 Phase 1/2 Proof-of-Concept Study Topline Data Call

Oct 24, 2022 at 8:00 AM EDT
Listen to webcast
VAX-24 Phase 1/2 Proof-of-Concept Study Topline Result 2.1 MB
Vaxcyte

ABOUT US

  • Corporate Profile
  • Management Team
  • Board of Directors
  • Scientific Advisory Board

OUR PROGRAMS

  • High-Fidelity Vaccines Engineered to Go the Distance
  • The Rising Consequences of Bacterial Infections
  • Vaccine Candidates Engineered to Overtake Convention
  • Posters / Publications

INVESTORS & MEDIA

  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Investor Resources
© 2023 Vaxcyte, Inc.
© 2023 Vaxcyte, Inc.